U.S. Health Officials Defend Rejection of Moderna’s Flu Vaccine

U.S. health officials have publicly defended the Food and Drug Administration's decision to reject Moderna's mRNA-based flu vaccine, a move that has sparked significant controversy within the medical community and created internal divisions at the agency. The FDA's refusal to evaluate the company's innovative mRNA flu shot has drawn widespread criticism from physicians and public health experts who argue that the technology could represent a major advancement in influenza prevention. While the exact reasons for the rejection remain somewhat unclear, the decision has highlighted tensions between regulatory caution and the potential benefits of cutting-edge vaccine technologies. Moderna, known for its successful COVID-19 mRNA vaccine, had hoped to apply its platform to seasonal flu, which affects millions annually and causes substantial healthcare burdens worldwide. The controversy comes at a time when public health agencies are increasingly focused on pandemic preparedness and the development of more effective flu vaccines.